The Ferrosorb suppository is primarily designed for patients who are unresponsive to oral iron supplements or who have experienced difficulties and/or unpleasant side effects when ingesting oral iron supplements.
Ferrosorb suppositories contain all the co-factors needed to facilitate conversion of elemental iron into ferritin and ultimately hemoglobulin. Ferrosorb also contains the most bioactive forms of the B vitamin complex including Folinic Acid which is more readily absorbed than Folic Acid, as well as the 2 bioactive forms of B12, pure methylcobalamin and cobamamide specialized forms which as essential blood cell production. Ferrosorb is ideal for 2 billion patients in the world suffering from iron and nutrtient deficient anemia and the symptoms related to iron deficiency and nutrient deficiency anemias.
Usual adult dosage is 1 suppository daily, or as directed by physician.
Ferrosorb 30 suppository package in 30 sealed suppository shells marked with a black line. It recommended that you store these suppositories in the refrigerator prior to use. Avoid excessive heat 40°C (104°
Contraindications: This
product is contraindicated in patients with a know hypersensitivity to
any of the ingredients. Patients sensitive to phospholipids should not
take this product. Hemochromatosis and hemosiderosis are
contraindications to iron therapy.
Warnings:
Folic acid alone is improper treatment in the
treatment of pernicious anemia and other megaloblastic anemias where
Vitamin B12 is deficient and not administered constantly. Ferrosorb
contains both Folic acid in the more bioactive form Folinic Acid and B12
in the metabolically active forms of Methylcobalamin and Cobamamide.
Accidental overdose of
iron-containing products is a leading cause of fatal poisoning in
children under the age 6 years old. Keep this product out of reach of
children. In case of accidental overdose, call a doctor or poison
control center immediately.
Precautions:
The type of anemia and the underlying cause or
causes should be determined before starting therapy with Ferrosorb.
Since the anemia may be a result of a systemic disturbance, such as
recurrent blood loss, the underlying cause or causes should be
corrected, if possible.
Folic Acid: Allergic sensitization, including anaphylactoid
reactions including urticaria (itching) has been reported following the
administration and of both oral and parenteral folinic acid. Pernicious
anemia should be excluded before using this product since folic acid
may mask the symptoms of pernicious anemia.
Pediatric Use: Safety and effectiveness in pediatric
patients have not been established.
Geriatric Use: Clinical studies on this product have not
been performed in sufficient numbers of subjects aged 65 and over to
determine whether elderly subjects respond differently from younger
subjects. In general, dose selection for an elderly patient should be
cautious, usually starting at the low end of the dosing range,
reflecting the greater frequency of decreased hepatic, renal, or cardiac
function, and of concomitant disease or other drug therapy.
Adverse Reactions with iron therapy may include
constipation, diarrhea, nausea, vomiting, darks stools and abdominal
pain. Adverse reactions with iron therapy are usually transient.
Allergic sensitization has rarely been reported following both oral and
parenteral administration of folic acid
Overdosage: The clinical course of acute iron over dosage
can be variable. Initial symptoms may include abdominal pain, nausea,
vomiting, diarrhea, tarry stools, melena, hematemesis, hypotension,
tachycardia, metabolic acidosis, hyperglycemia, dehydration, drowsiness,
pallor, cyanosis, lassitude, seizures, shock and coma.
